Diflucan 150 mg 1 capsule

Tradename

Diflucan

Diflucan

Composition

Each hard gelatin capsule contains:

Fluconazole 150mg

Auxiliary components: lactose monohydrate, corn starch, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate.

Properties

fluconazole — has the property of effectively inhibiting the synthesis of sterols in fungal cells. The effectiveness of Diflucan has been proven against yeast and yeast-like fungi (Candida spp, Cryptococcus neoformans), molds (Histoplasma capsulatum, Blastomyces dermatitides), dermatophytes (Trichophyton spp, Microsporum immitides), dimorphic forms (Coccidio.

Indications

cryptococcosis, including cryptococcal meningitis and infections at other sites (eg, lungs, skin), incl. in patients with a normal immune response and AIDS patients, organ transplant recipients and patients with other forms of immunodeficiency; supportive therapy to prevent relapse of cryptococcosis in AIDS patients. Generalized candidiasis, including candidemia, disseminated candidiasis, and other forms of invasive candidiasis, such as infections of the peritoneum, endocardium, eyes, respiratory and urinary tract, incl. in patients with malignant tumors in intensive care units and receiving cytotoxic or immunosuppressive drugs, as well as in patients with other factors predisposing to the development of candidiasis.

Candidiasis of the mucous membranes, including the mucous membranes of the mouth and pharynx, esophagus, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic atrophic oral candidiasis (associated with wearing dentures), incl. in patients with normal and suppressed immune function. Prevention of recurrence of oropharyngeal candidiasis in AIDS patients.

Genital candidiasis; acute or recurrent vaginal candidiasis; prevention in order to reduce the frequency of relapses of vaginal candidiasis (4 or more episodes per year); candidal balanitis. Prevention of fungal infections in patients with malignant tumors who are prone to such infections as a result of cytotoxic chemotherapy or radiation therapy.

Contraindications

hypersensitivity to fluconazole, related azole compounds or any of the excipients in the composition. Fluconazole should not be taken with terfenadine, cisapride or ergot derivatives. During pregnancy and breastfeeding.

Precautionary measures:

with caution in patients with renal and hepatic dysfunction. The drug has been associated with rare cases of severe liver toxicity. In cases of hepatotoxicity associated with fluconazole, there was no clear relationship with the total daily dose, duration of therapy, gender or age of the patient. It is reversible upon discontinuation of therapy. The patient should be informed of the symptoms of a serious hepatic effect (asthenia, anorexia, persistent nausea, vomiting and jaundice are important). Fluconazole treatment should be discontinued immediately and the patient should see a doctor.

Side effects

from the gastrointestinal tract: decreased appetite, nausea, constipation or diarrhea, flatulence, abdominal pain, toothache, rarely liver dysfunction (icterus of the sclera, jaundice, hyperbilirubinemia, increased ALT, AST and ALP activity). From the nervous system: headache, dizziness, excessive

I am tired, rarely — convulsions. From the side of hematopoietic organs: rarely — leukopenia, thrombocytopenia (bleeding, petechiae), neutropenia, agranulocytosis. Allergic reactions: skin rash, rarely — exudative erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), anaphylactoid reactions. Others: rarely — impaired renal function, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

Pregnancy and lactation. Data from several hundred pregnant women who received standard doses (<200 mg / day) of fluconazole, given as a single or multiple dose in the first trimester, do not show unwanted fetal defects. Despite this, the use of the drug in pregnant women is inappropriate, with the exception of severe or life-threatening forms of fungal infections, when the potential benefit from the use of fluconazole to the mother significantly outweighs the risk to the fetus.